Eficacia y seguridad de vacunas contra SARS-CoV-2 en pacientes con enfermedades reumatológicas autoinmunes

Los pacientes con enfermedades reumatológicas autoinmunes tienen mayor riesgo de infección por SARS-CoV-2 por factores propios de la enfermedad, así como los derivados por el tratamiento, con el desarrollo de vacunas se ha priorizado la inmunización en este grupo de pacientes, no obstante, la eficacia y seguridad de vacunas contra SARS-CoV-2 no se ha estudiado en esta población por su exclusión en los ensayos clínicos de fase II-III. Objetivo. analizar la eficacia y seguridad de vacunas contra SARS-CoV-2 en pacientes con enfermedades reumatológicas autoinmunes. Metodología. Se realizó una revisión sistemática, usando la declaración PRISMA, como criterios de búsqueda fueron considerados publicaciones portugués, inglés y español, relacionada con la eficacia y seguridad de vacunas contra SARS-CoV-2 durante los últimos 6 años. La búsqueda de artículos se desarrolló en las bases de datos como PubMed, Scopus y ScienceDirect publicados en idiomas inglés, portugués y español publicados durante los últimos 6 años hasta la actualidad. Resultados. Se encontraron 79 artículos, 27 en PubMed, en Google Scholar 52; la cantidad se redujo a 60, eliminando 19 por duplicidad, 27 por resumen de artículo, luego de un análisis exhaustivo del contenido de la información para así obtener un total de 8 artículos para el análisis del estudio. Conclusión. La eficacia de vacunas contra SARS-CoV-2 en pacientes con enfermedades reumatológicas se encuentra reducida, atribuida al uso de glucocorticoides y de terapias inmunosupresoras en las que se destaca rituximab, micofenolato de mofetilo y metotrexato, mientras que la seguridad basada en los efectos adversos es similar a los encontrados en la población general.

Patients with autoimmune rheumatologic diseases have a higher risk of infection by SARS-CoV-2 due to factors inherent to the disease, as well as those derived from treatment. With the development of vaccines, immunization has been prioritized in this group of patients; however, the efficacy and safety of vaccines against SARS-CoV-2 has not been studied in this population due to their exclusion in phase II-III clinical trials. Objective. to analyze the efficacy and safety of vaccines against SARS-CoV-2 in patients with autoimmune rheumatologic diseases. Methodology. A systematic review was performed, using the PRISMA statement, as search criteria were considered Portuguese, English and Spanish publications, related to the efficacy and safety of vaccines against SARS-CoV-2 during the last 6 years. The search for articles was developed in databases such as PubMed, Scopus and ScienceDirect published in English, Portuguese and Spanish published during the last 6 years to date. Results. A total of 79 articles were found, 27 in PubMed, 52 in Google Scholar; the number was reduced to 60, eliminating 19 for duplicity, 27 for article ABSTRACT, after an exhaustive analysis of the content of the information to obtain a total of 8 articles for the analysis of the study. Conclusion. The efficacy of vaccines against SARS-CoV-2 in patients with rheumatologic diseases is reduced, attributed to the use of glucocorticoids and immunosuppressive therapies in which rituximab, mycophenolate mofetil and methotrexate stand out, while safety based on adverse effects is similar to those found in the general population.

Pacientes com doenças reumatológicas autoimunes têm maior risco de infecção pelo SARS-CoV-2 devido a fatores inerentes à doença, bem como àqueles derivados do tratamento. Com o desenvolvimento de vacinas, a imunização tem sido priorizada nesse grupo de pacientes; no entanto, a eficácia e a segurança das vacinas contra o SARS-CoV-2 não foram estudadas nessa população devido à sua exclusão dos ensaios clínicos de fase II-III. Objetivo. Analisar a eficácia e a segurança das vacinas contra o SARS-CoV-2 em pacientes com doenças reumatológicas autoimunes. Metodologia. Foi realizada uma revisão sistemática utilizando a declaração PRISMA, tendo como critério de busca publicações em português, inglês e espanhol relacionadas à eficácia e à segurança de vacinas contra o SARS-CoV-2 nos últimos 6 anos. A busca de artigos foi desenvolvida em bancos de dados como PubMed, Scopus e ScienceDirect, publicados em inglês, português e espanhol, publicados nos últimos 6 anos até o presente. Resultados. Foram encontrados 79 artigos, 27 no PubMed, 52 no Google Scholar; o número foi reduzido para 60, eliminando 19 por duplicidade, 27 por resumo do artigo, após uma análise exaustiva do conteúdo das informações para obter um total de 8 artigos para a análise do estudo. Conclusões. A eficácia das vacinas SARS-CoV-2 em pacientes com doenças reumatológicas é reduzida, atribuída ao uso de glicocorticoides e terapias imunossupressoras, incluindo rituximabe, micofenolato mofetil e metotrexato, enquanto a segurança baseada em efeitos adversos é semelhante à encontrada na população em geral.

Adherence to treatment of children and adolescents recently diagnosed with auto-immune Rheumatic Diseases during the COVID-19 pandemic

Abstract Objectives Adherence problems have a great impact on auto-immune Rheumatic Diseases (AIRD). The COVID-19 pandemic may have worsened treatment adherence. The aims of this study were to measure treatment adherence to identify an earlier risk of poor adherence and measure families' satisfaction with the health service during the pandemic. Methods Prospective observational study with 50 parents/children and adolescents with recent AIRD diagnosis. Initially, they answered questions (demographic data, disease) and completed the Pediatric Rheumatology Adherence Questionnaire (PRAQ), after 6 months they completed the Morisky-Green Test (MGT), Brief Medication Questionnaire (BMQ), Compliance Questionnaire for Rheumatology (CQR-19) and Pediatric Quality of Life Inventory Questionnaire 3.0 (PedsQlTM-SSS). The patient's medical records from the previous 12 weeks were reviewed for global and medication adherence data. Results The mean global adherence score was 94.3 ± 10.0, for medication adherence 97.3 ± 9.3, and for PRAQ questionnaire 5.2 ± 1.5. The authors observed agreement between MGT, BMQ, CQR-19, PedsQLTM-SSS scores and medication adherence rate, but not with global adherence rate. There were no associations between demographic characteristics, disease diagnosis, and adherence. No associations between PRAQ scores and values and global/medication adherence rates were observed. No variables were shown to be predictors of good adherence. The mean PedsQLTM-SSS rate was 92.1 ± 6.8. Conclusion The high values of MGT, BMQ, CQR-19 questionnaire scores were in agreement with the medication adherence rate. Despite the pandemic, the global and medication adherence rates were good. It was not possible to demonstrate the PRAQ's predictive power. The authors weren't able to establish an association between families' satisfaction and treatment adherence rates.

Cultural adaptation and validation of the COPCORD questionnaire for the detection of rheumatic diseases in the indigenous Misak population

Introduction: The objective was to adapt and valídate in a culturally sensitive way the methodology of the community-oriented programme for the control of rheumatic diseases (COPCORD) in the indigenous Misak community of Colombia. Material and methods: A culturally sensitive validation of the COPCORD questionnaire in Spanish was carried out, translating into the nam trik wam language used by the Misak community of Guambia town. It was adapted to the context of this population and later a back-translation to Spanish was carried out. Finally, it was validated applying the survey with the support of bilingual translators. Participants with pain, stiffness or swelling in any joint in the previous 7 days and/or at any time in life were evaluated by physicians and physiotherapists and were then, upon confirming the diagnosis of a musculoskeletal disorder, subsequently examined by a rheumatologist. Results: In this population (n = 106), 58.5% were women with an average age of 45.5 years. In the last 7 days, 51 subjects (48.1%) reported having musculoskeletal pain and 7 (44.3%) reported pain at some time in their life. Of those who received treatment, 53.1% reported using traditional medicine, 34.4% homeopathic treatment, and 25% allopathic treatment. The COPCORD Misak demonstrated an adequate capacity to detect musculoskeletal disorders, with a sensitivity of 63.3% and a specificity of 80.3%, with a positive likelihood ratio of 3.2, and area under the curve of.71. Conclusion: The COPCORD methodology is a valid screening tool to detect musculoskeletal disorders in the Misak community.

Introducción: El objetivo fue adaptar y validar, de forma culturalmente sensible, la metodología del Programa orientado a la comunidad para el control de enfermedades reumáticas (COPCORD) en la comunidad indígena misak de Colombia. Material y métodos: Se realizó una validación culturalmente sensible del cuestionario Copcord en español, que se tradujo al nam trik wam, lengua usada por el pueblo misak del resguardo de Guambia. El cuestionario se adecuó al contexto de esta población y posteriormente se llevó a cabo una retrotraducción al español. Por último, se validó aplicando la encuesta con el apoyo de traductores bilingües. Los participantes con dolor, rigidez o hinchazón en cualquier articulación en los siete días previos, o en cualquier momento de la vida, fueron evaluados por médicos y fisioterapeutas. Al confirmarse el diagnóstico de una enfermedad musculoesquelética los participantes eran examinados por un reumatólogo. Resultados: De la población estudiada (n = 106) el 58,5% fueron mujeres, con una edad promedio de 45,4 arios. En los últimos siete días, 51 sujetos (48,1%) informaron tener dolor musculoesquelético y siete (44,3%) refirieron dolor en algún momento de su vida. Quienes recibieron tratamiento reportaron el uso de medicamentos tradicionales en un 53,1% de los casos, homeopáticos en el 34,4% y alopáticos en el 25%. El cuestionario COPCORD Misak demostró una adecuada capacidad para detectar los trastornos musculoesqueléticos, con una sensibilidad del 63,3%, una especificidad del 80,3%, una razón de verosimilitud positiva de 3,2 y un área bajo la curva de 0,71. Conclusión: La metodología COPCORD es una herramienta válida de cribado de enfermedades musculoesqueléticas en el pueblo misak.

Tuberculosis in children and adolescents with rheumatic diseases using biologic agents: an integrative review / Tuberculose em crianças e adolescentes com doenças reumáticas em uso de medicamentos biológicos: revisão integrativa

ABSTRACT Objective: To conduct a bibliographic review on tuberculosis (TB) disease in children and adolescents with rheumatic diseases, being managed with biologic therapy. Data source: An integrative review with a search in the U.S. National Library of Medicine and the National Institutes of Health (PubMed) using the following descriptors and Boolean operators: (["tuberculosis"] AND (["children"] OR ["adolescent"]) AND ["rheumatic diseases"] AND (["tumor necrosis factor-alpha"] OR ["etanercept"] OR ["adalimumab"] OR ["infliximab"] OR ["biological drugs"] OR ["rituximab"] OR ["belimumab"] OR ["tocilizumab"] OR ["canakinumab"] OR ["golimumab"] OR ["secukinumab"] OR ["ustekinumab"] OR ["tofacitinib"] OR ["baricitinib"] OR ["anakinra"] OR ["rilonacept"] OR ["abatacept"]), between January 2010 and October 2021. Data synthesis: Thirty-seven articles were included, with the total number of 36,198 patients. There were 81 cases of latent tuberculosis infection (LTBI), 80 cases of pulmonary tuberculosis (PTB), and four of extrapulmonary tuberculosis (EPTB). The main rheumatic disease was juvenile idiopathic arthritis. Among LTBI cases, most were diagnosed at screening and none progressed to TB disease during follow-up. Of the TB cases using biologics, most used tumor necrosis factor-alpha inhibitors (anti-TNFα) drugs. There was only one death. Conclusions: The study revealed a low rate of active TB in pediatric patients using biologic therapy. Screening for LTBI before initiating biologics should be done in all patients, and treatment, in cases of positive screening, plays a critical role in preventing progression to TB disease.

RESUMO Objetivo: Fazer um levantamento bibliográfico referente à tuberculose (TB) em crianças e adolescentes com doenças reumáticas, em uso de imunobiológicos. Fonte de dados: Revisão integrativa com busca na base United States National Library of Medicine (PubMed) utilizando os descritores e operadores booleanos: (["tuberculosis"] AND (["children"] OR ["adolescent"]) AND ["rheumatic diseases"] AND (["tumor necrosis fator-alpha"] OR ["etanercept"] OR ["adalimumab"] OR ["infliximab"] OR ["biological drugs"] OR ["rituximab"] OR ["belimumab"] OR ["tocilizumab"] OR ["canakinumab"] OR ["golimumab"] OR ["secukinumab"] OR ["ustekinumab"] OR ["tofacitinib"] OR ["baricitinib"] OR ["anakinra"] OR ["rilonacept"] OR ["abatacept"]), entre janeiro de 2010 e outubro de 2021. Síntese de dados: Trinta e sete artigos foram incluídos, com o total de 36.198 pacientes. Houve 81 casos de tuberculose latente (ILTB), 80 casos de tuberculose pulmonar (TBP) e quatro casos de tuberculose extrapulmonar (TBEP). A principal doença reumática foi a artrite idiopática juvenil. Entre os casos de ILTB, a maioria foi diagnosticada no rastreio e nenhum evoluiu para a TB. Dos casos de TB em uso de imunobiológicos, a maioria utilizava fármacos antiTNFα. Houve somente um caso de óbito. Conclusões: O estudo demonstrou baixa taxa de TB nos pacientes pediátricos em uso de imunobiológicos. O rastreio para ILTB antes do início da terapia com agentes biológicos deve ser realizado em todos os pacientes, e o tratamento, nos casos de rastreio positivo, é importante para evitar a progressão para TB doença.

Prevalence and factors associated with flares following COVID-19 mRNA vaccination in patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: a national cohort study

Abstract Objective To determine prevalence and factors associated with flares post Coronavirus disease 2019 (COVID-19) mRNA vaccination in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and spondyloarthritis (SpA). Methods A retrospective multi-centre study was conducted (January 2021 to February 2022). Data were collected during index visit, defined as first post-vaccine visit in which the patient had a physician-defined flare, or if at least 3 months had elapsed since first vaccine dose, whichever came first. Factors associated with flares were identified using mixed effects Cox regression and expressed as hazard ratio (HR) and 95% confidence interval (CI). Results Total of 2377 patients were included (1563 RA, 415 PsA and 399 SpA). Among patients with RA, PsA and SpA, 21.3%, 24.1% and 21.8% experienced a flare respectively. Of those who experienced a flare, only 10.2%, 11.0% and 14.9% were severe in patients with RA, PsA and SpA respectively. Patients with low or moderate/high disease were more likely to flare compared to those in remission in patients with RA only (HR: 1.68, 95% CI 1.22-2.31; HR: 2.28, 95% CI 1.50-3.48, respectively). Receiving the Moderna vaccine was associated with a higher HR of flare compared to the Pfizer vaccine in patients with PsA only (HR: 2.21, 95% CI 1.20-4.08). Patients who had two vaccine doses were found to be less likely to flare (HR: 0.08, 95% CI 0.06-0.10). HRs of flares were not significantly different among RA, PsA and SpA. Conclusion About one-fifth of patients experienced a disease flare post COVID-19 mRNA vaccination, but most flares were non-severe. Patients with active disease prior to vaccination should be monitored closely for disease flares, especially in patients with RA.

Does the use of panoramic radiography add information in the temporomandibular joint evaluation in Juvenile Idiopathic Arthritis patients? A case control study

Abstract Objective To determine the frequency of radiographic changes in the temporomandibular joint, in a representative population of patients with Juvenile Idiopathic Arthritis (JIA) and to compare with findings in healthy controls matched by sex and age. Patients and Methods One hundred and thirty-seven panoramic radiographies (PR) from JIA patients of a pediatric rheumatology outpatient clinic were prospectively evaluated and compared to 137 PR from healthy individuals. Results 102 (74.5%) JIA patients and 47 (34.3%) controls showed at least one radiological alteration (p < 0.001). The following radiographic alterations were more frequently observed in JIA patients than in controls: erosion (p < 0.001), altered condylar morphology (p < 0.001), disproportion between condylar process and the coronoid process (p < 0.001) and accentuated curve in the antegonial notch (p = 0.002). Twenty patients (14.6%) presented the four radiographic alterations simultaneously compared to only two controls (1.5%) (p < 0.001). Conclusion Due to the difference in the frequency of findings in the PR of patients and controls, we concluded that PR has value as a screening tool. In the presence of major changes in the mandible head in the PR of patients with a confirmed diagnosis of JIA, MRI should be considered to detect an active inflammatory process in this joint.

Interpretation of the 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty / 中华骨科杂志

The American College of Rheumatology (ACR) and the American Association of Hip and Knee Surgeons (AAHKS) convened a writing group to develop a consensus report on the management of anti-rheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty in June 2022. In particular, the consensus provides significant updates on target synthetic disease modifying anti-rheumatic drugs and perioperative medication management in patients with systemic lupus erythematosus, as well as the addition of newly approved antirheumatic medications for administration. This article will interpret the consensus and provide a reference for the perioperative management of antirheumatic medications for hip and knee arthroplasty in patients with rheumatic diseases in China.

Conception of National Biologics Registry for Pediatric Rheumatology: Need of the Hour and the Way Forward

The outcome for children with rheumatic diseases has been dramatically altered by the use of biological therapies. Increasing use of these agents will need careful monitoring for long term safety, particularly in children. Current data on safety of these drugs stem exclusively from Western literature. There is clear need for a registry of all children with rheumatic diseases who are commenced on biological agents to ensure appropriate pharmacovigilance. In this perspective, we discuss the need for and the role of a biologics registry for children with rheumatic diseases in India.

Síndrome de Guillain-Barré como manifestación neurológica autoinmune asociado a COVID-19: Una revisión de la literatura / no

La enfermedad por coronavirus (COVID-19) producida por el SARS-CoV-2 ha sido un reto para los servicios de salud en todo el mundo. La pandemia se ha extendido ampliamente con más de 80 millones de casos confirmados y más de un millón de muertes a nivel mundial, por lo que ha estado bajo constante investigación para entender todos los aspectos de la enfermedad. Recientemente se han reportado varios casos de pacientes con síndrome de Guillain-Barré asociado a COVID-19 como manifestación principal, convirtiéndola en la primera enfermedad neurológica autoinmune desencadenada por SARS-CoV-2; sin embargo, es necesario obtener más información para entender completamente los mecanismos inmunopatogénicos implicados en esta asociación.

The coronavirus disease (COVID-19) caused by SARS-CoV-2 has been a challenge for health services around the world. The pandemic has spread widely, with more than 80 million confirmed cases and more than one million deaths globally. There have been many studies to understand all aspects of the disease. Recently, several cases have been reported of patients with Guillain-Barré syndrome associated with COVID-19 as the main manifestation. As it may be one of the first autoimmune neurological diseases triggered by SARS-CoV-2, it is necessary to obtain more information to fully understand the immunopathogenic mechanisms involved in this association.

Systemic sclerosis in a patient with Turner syndrome: A case report and a review of associated autoimmune diseases

Turner's syndrome (TS) is one of the most common sex chromosome disorders caused by numeric or structural abnormalities of the X chromosome. A case of TS and Systemic Sclerosis (SSc) is reported, along with a summary of all associated TS/autoimmune diseases described in English literature from 1948 to 2020, using a search in MEDLINE (Pubmed). A 32-year-old woman affected by TS was seen due to inflammatory arthralgia in small joints and dysphagia, as well as a two-year history of Raynaud's phenomenon and puffy hands. Biohumoural laboratory tests and severity scales revealed changes that allowed us to diagnose SSc. This case report emphasises the role played by sex hormones and chromosomal abnormalities in the pathogenesis of autoimmune disorders, and to our knowledge, this is the only case described in literature of a TS patient who developed SSc.

El síndrome de Turner (TS) es uno de los trastornos cromosómicos sexuales más comunes causados por anomalías numéricas o estructurales del cromosoma X. En este documento informamos de un caso de TS y esclerosis sistémica (SSc) y resumimos toda la asociación de TS/enfermedades autoinmunes descrita en la literatura inglesa de 1948 a 2020, encontrada buscando en MEDLINE (PubMed). Una mujer de 32 arios afectada por TS acudió a nuestra observación debido a la artralgia inflamatoria en pequenas articulaciones y disfagia y 2 anos de historia del fenómeno de Raynaud y las manos hinchadas. El laboratorio biohumoral y las pruebas instrumentales revelaron alteraciones que nos permitieron diagnosticar SSc. Nuestro informe de caso hace hincapié en el papel desempefíado por las hormonas sexuales y las anomalías cromosómicas en la patogénesis del trastorno autoinmune; y hasta nuestro conocimiento, este es el único caso descrito en la literatura de un paciente TS que desarrolló SSc.

Clinical and immunological factors associated with lupus nephritis in an Argentine patient population: A cross-sectional study

Introduction: In recent decades, the prevalence of systemic lupus erythematosus (SLE) has increased thanks to early detection and the impact of new therapies on the survival of those affected. Up to 90% will have histopathological signs of kidney disease in the first 3 years of the disease, but lupus nephritis of clinical relevance will appear in 50% of cases, affecting kidney function and mortality. Despite aggressive therapeutic strategies, the prognosis of patients with LN remains unfavourable, mainly due to the high risk of progression to end-stage renal disease (10%-20%) and mortality from all causes. Objective: To describe the clinical and immunological risk factors of a group of patients with lupus, comparing clinical and serological characteristics in relation to renal involvement to establish possible associations. Materials and methods: Cross-sectional study in which 87 patients with SLE were included. Clinical and immunological variables were analyzed. Bivariate and multivariate analyses were performed using the presence of nephritis as an outcome. Results: The prevalence of lupus nephritis was 59%. The significantly associated variables were arterial hypertension (OR 3.1, 95% CI 1.02-9.40), age of onset of lupus less than 25 years (OR 2.7, 95% CI 1.08-6.73), the presence of reticular livedo (OR 4.1, 95% CI 1.09-15.7), positive anti-DNA (OR 2.9, 95% CI 1.18-7.24) and low levels of complement (OR 4.0, 95% CI 1.64-10.2). Conclusions: Urinary sediment abnormalities were the most common renal manifestation and lupus debut before the age of 25 seems to increase the risk of developing nephritis. Future research is required for a better explanation of the associations found.

Introducción: En las últimas décadas, la prevalencia del lupus eritematoso sistémico (LES) se ha incrementado gracias a la detección temprana y al impacto de las nuevas terapias en la sobrevida de los afectados. Hasta el 90% de ellos tendrá signos histopatológicos de afección renal en los primeros 3 arios de la enfermedad, pero la nefritis lúpica (NL) de relevancia clínica aparecerá en el 50% de los casos, afectando la función renal y la mortalidad. A pesar de las estrategias terapéuticas agresivas, el pronóstico de los pacientes con NL sigue siendo desfavorable, principalmente debido al alto riesgo de progresión a enfermedad renal crónica terminal (10-20%) y de mortalidad por todas las causas. Objetivo: Describir los factores de riesgo clínicos e inmunológicos de un grupo de pacientes con lupus, comparando características clínicas y serológicas en relación con el compromiso renal, a fin de establecer posibles asociaciones. Materiales y métodos: Estudio de corte transversal en el que se incluyeron 87 pacientes con LES. Se analizaron variables clínicas e inmunológicas. Los análisis bivariado y multivariados se realizaron utilizando la presencia de nefritis como desenlace. Resultados: La prevalencia de NL fue del 59%. Las variables asociadas significativamente fueron hipertensión arterial (OR: 3,1; IC 95%: 1,02-9,40), edad de aparición del lupus menor de 25 años (OR: 2,7; IC 95%: 1,08-6,73), presencia de livedo reticularis (OR: 4,1; IC 95%: 1,0915,7), anti-DNA positivo (OR: 2,9; IC 95%: 1,18-7,24) y niveles bajos de complemento (OR: 4,0; IC 95%: 1,64-10,2). Conclusiones: Las anormalidades en el sedimento urinario fueron la manifestación renal más común, en tanto que el inicio lúpico antes de los 25 años parece incrementar el riesgo de desarrollar nefritis. Se requieren futuras investigaciones que den una mejor explicación a las asociaciones encontradas.

Perception of quality of life in patients with systemic lupus erythematosus. A five-year study

Introduction: Systemic lupus erythematosus is an autoimmune, inflammatory, and chronic disease that considerably affects the perception of health-related quality of life. Objective: To determine the perception of quality of life in patients with systemic lupus erythematosus. Methodology: Descriptive and correlational study; universe of 143 patients and a sample of 127 patients to whom the Short Form 36 questionnaire was applied to determine perception of health-related quality of life; the SLEDAI questionnaire to determine clinical activity, the SLICC to identify organic damage and the Morisky Green test to identify pharmacological adherence. Pearson's correlation coefficient was used to determine the association between the study variables. Results: Mean age of 32.83 years, predominance of female patients (92.91%) and with disease progression of between one and 5 years (69.29%). Of the patients, 75.59% had at least one associated comorbidity and 80.31% were considered pharmacological adherents. The overall quality of life perception score was 61.02 points in women and 59.03 points in men. In general, the most affected dimensions were the emotional role in women and vitality in men. Conclusions: The increase in disease progression time, the presence of associated comorbidities and pharmacological non-adherence were variables that determined a decrease in the mean scores of perception of quality of life. There was a strong negative correlation between clinical activity of the disease and perception of quality of life.

Introducción: El lupus eritematoso sistémico es una enfermedad autoinmune, inflamatoria y crónica que afecta considerablemente la percepción de la calidad de vida relacionada con la salud. Objetivo: Determinar la percepción de la calidad de vida en pacientes con lupus eritematoso sistémico. Metodología: Estudio descriptivo y correlacional, universo de 143 pacientes y muestra de 127, a los cuales se les aplicó el cuestionario Short Form 36 para determinar la percepción de la calidad de vida relacionada con la salud, el cuestionario Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), a fin de establecer la actividad clínica, el SLICC, con el propósito de identificar el daño orgánico, y el test de Morisky-Green, a efectos de evaluar la adherencia farmacológica. Se utilizó coeficiente de correlación de Pearson para determinarla asociación entre las variables del estudio. Resultados: Promedio de edad de 32,83 anos, predominio de pacientes femeninas (92,91%) y con tiempo de evolución entre uno y cinco anos (69,29%). El 75,59% de los pacientes presentó al menos una comorbilidad asociada y el 80,31% se consideró adherente farmacológico. La puntuación de percepción de la calidad de vida global fue de 61,02 puntos en mujeres y 59,03 puntos en hombres. De forma general, las dimensiones más afectadas fueron el rol emocional en las féminas y la vitalidad en los hombres. Conclusiones: El aumento del tiempo de evolución de la enfermedad, la presencia de comorbilidades asociadas y la no adherencia farmacológica constituyeron variables que determinaron una disminución de las puntuaciones medias de percepción de la calidad de vida. Hubo correlación negativa fuerte entre actividad clínica de la enfermedad y percepción de la calidad de vida.

Evaluación de la calidad de vida de los pacientes con osteoartritis sintomática de rodilla / Evaluation of the quality of life of patients with symptomatic osteoarthritis of the knee

Introducción: El estudio de la morbilidad y el impacto de la enfermedad en el estilo de vida se conocen como medición de la calidad de vida. Objetivo: Evaluar el nivel de la calidad de vida de pacientes con diagnóstico de osteoartritis sintomática de rodilla. Métodos: Se realizó una investigación descriptiva, transversal, en pacientes con diagnóstico de osteoartritis sintomática de rodilla del Centro de Referencia de Enfermedades Reumáticas entre noviembre de 2017 a junio de 2020. La muestra quedó conformada por 213 pacientes, evaluados con el índice de WOMAC de calidad de vida. Resultados: En el grupo de edad de 55-64 años y discapacidad grave se obtuvo la mayor frecuencia de casos (18,3 por ciento; 39). Los pacientes con sobrepeso y discapacidad grave representaron el 28,2 por ciento (60). Predominaron los que tuvieron más de 5 años de evolución de la enfermedad y discapacidad grave (21,0 por ciento; 45). El mayor porcentaje de pacientes se presentó con deformidad de genu varo y discapacidad grave (29,6 por ciento; 63). Hubo relación entre la calidad de vida y el sexo, el índice de masa corporal y el tiempo de evolución de la enfermedad. Conclusiones: La intensidad del dolor se relaciona con un grado radiográfico avanzado, en tanto la calidad de vida con el sexo, el tiempo de evolución de la enfermedad y el índice de masa corporal(AU)

Introduction: The study of morbidity and the impact of the disease on lifestyle is known as quality of life measurement. Objective: To evaluate the level of quality of life of patients diagnosed with symptomatic osteoarthritis of the knee. Methods: A descriptive, cross-sectional investigation was carried out in patients diagnosed with symptomatic knee osteoarthritis from the Reference Center for Rheumatic Diseases between November 2017-June 2020. The sample was made up of 213 patients, who were evaluated with the WOMAC index of quality of life. Results: In the age group of 55-64 years and severe disability, the highest frequency of cases was obtained (18.3percent; 39). Patients with overweight and severe disability represented 28.2percent60). Those who had more than 5 years of evolution of the disease and severe disability prevailed (21.0percent; 45). The highest percentage of patients presented with genu varus deformity and severe disability (29.6percent; 63). There was a relationship between quality of life and sex, body mass index and the time of evolution of the disease. Conclusions: The intensity of the pain is related to an advanced radiological degree, while the quality of life is related to sex, the time of evolution of the disease and the body mass index(AU)

Estado actual y retos futuros en el tratamiento de las enfermedades reumáticas / Current status and future challenges in the treatment of rheumatic diseases

Las nuevas estrategias, que incluyen el diagnóstico y el tratamiento tempranos, el enfoque de tratamiento dirigido a un objetivo, la remisión como ese objetivo principal del tratamiento, la participación de los pacientes en las decisiones terapéuticas, junto con el desarrollo de nuevos tratamientos efectivos, han cambiado las expectativas de los reumatólogos y de los pacientes con enfermedades reumáticas. Todavía existen, sin embargo, importantes desafíos tales como la seguridad a largo plazo de los tratamientos actuales y poder escoger tratamientos más individualizados y eficaces, de forma tal de elegir el mejor tratamiento para cada paciente. El futuro, como en el resto de la medicina, probablemente sea la prevención del desarrollo de enfermedades reumáticas. Discutiremos estos temas en esta revisión. (AU)

New strategies, including early diagnosis and treatment, targeted therapy, remission as the main objective of treatment, patient involvement in therapeutic decision-making, and the development of new effective therapies, have changed the expectations of rheumatologists and patients with rheumatic diseases.There are still serious challenges, such as the long-term safety of current treatments and the ability to make more individualized and effective treatments to choose the best treatment for each patient. The future, as that of the whole of medical science, will probably lie in preventing the development of rheumatic diseases. We will discuss these issues in this review. (AU)

Hospital outcomes in patients evaluated by rheumatology in a Colombian historical cohort

Introduction: Hospitalized patients with systemic autoimmune rheumatic diseases (SARDs) generate high impact in clinical terms. Objectives: To characterize the study population and estimate risk factors associated with the presence of adverse outcomes in hospitalized patients consulting rheumatology at Clínica Imbanaco between January 2013 and December 2019. Methods: We analyzed a historical cohort of hospitalized patients who were evaluated by rheumatology. The population was classified as follows: group 1, patients with new onset diagnosed SARDs; group 2, patients with known diagnosed SARDs; group 3, patients without diagnosed SARDs; and group 4, patients with unconfirmed suspicion of SARDs. A composite adverse outcome was defined if at least one of the following occurred: (1) hospital mortality, (2) admission to the intensive care unit, (3) hospital infection, or (4) readmission. Results: Information was collected from 327 hospitalization events (307 patients). The median age was 48 (34-63) years and 222 (72.3%) were women. The composite adverse outcome occurred in 136 (41.5%) hospitalization events. Group 2 had the highest number of adverse outcomes (61/128; 47.6%). The variables associated with the worst outcomes were cardiovascular diagnosis at admission (OR = 4.63; CI: 1.60-13.43; p = 0.005), longer hospital stay (OR = 1.04; CI: 1.01-1.07; p = 0.005), and a treating specialty other than internal medicine (OR = 2.79; CI: 1.26-6.17; p = 0.011). Male sex (OR = 0.29; CI: 0.12-0.66; p = 0.004), having special health coverage (OR = 0.39; CI: 0.15-.099; p = 0.047), and hemoglobin > 11.4 g/dL (OR = 0.82; CI: 0.69-0.99; p = 0.039) were the factors associated with lower odds of developing the composite outcome. Conclusions: In this historical cohort, the group of patients with known diagnosed SARDs presented a higher number in percentage terms of adverse outcomes. The most frequent adverse outcomes were admission to the ICU and hospital readmission.

Introducción: Los pacientes hospitalizados con enfermedades reumáticas o autoinmunes sistémicas (ERAS) generan gran impacto en términos clínicos. Objetivos: Caracterizar a la población y estimar factores de riesgo asociados con la presencia de desenlaces adversos en pacientes evaluados hospitalariamente por reumatología en la Clínica Imbanaco durante los arios 2013-2019. Metodología: Se analizó una cohorte histórica de pacientes hospitalizados que fueron evaluados por reumatología. La población se clasificó así: grupo 1, pacientes con ERAS diagnosticada de novo; grupo 2, pacientes con ERAS diagnosticada conocida; grupo 3, pacientes sin ERAS diagnosticada; y grupo 4, pacientes con sospecha no confirmada de ERAS. Se definió un desenlace adverso compuesto si se presentó al menos uno de los siguientes casos: 1) mortalidad hospitalaria; 2) ingreso a la unidad de cuidado intensivo; 3) infección intrahospitalaria; 4) reingreso. Resultados: En un total de 327 eventos de hospitalización (307 pacientes), la mediana de edad fue 48 (34-63) años y 222 (72,3%) fueron mujeres. El desenlace adverso compuesto se presentó en 136 (41,5%) eventos. El grupo 2 tuvo mayor número de desenlaces adversos (61/128; 47,6%). Las variables asociadas con peores resultados fueron: diagnóstico inicial cardiovascular (OR = 4,63; IC: 1,60-13,43; p = 0,005), mayor estancia hospitalaria (OR = 1,04; IC: 1,01-1,07; p = 0,005) y tener una especialidad tratante diferente a medicina interna (OR = 2,79; IC: 1,266,17; p = 0,011). El sexo masculino (OR = 0,29; IC: 0,12-0,66; p = 0,004), pertenecer a un régimen especial de salud (OR = 0,39; IC: 0,15-0,99; p = 0,047) y tener hemoglobina > 11,4 g/dL (OR = 0,82; IC: 0,69-0,99; p = 0,039) fueron factores asociados con menor oportunidad de desarrollar el desenlace compuesto. Conclusiones: En esta cohorte histórica se encontró que porcentualmente el grupo de pacientes con ERAS diagnosticadas conocidas presentó mayor número de desenlaces adversos, entre los que se destacan para el mismo grupo, el ingreso a UCI y el reingreso hospitalario.

Effect of pharmacotherapy on fibromyalgia: an overview of systematic reviews / Efeito da farmacoterapia na fibromialgia: uma overview de revisões sistemáticas

Fibromyalgia is a debilitating and chronic pain processing disorder, in which the proportion of patients who achieve good results with pharmacotherapy is small. However, choosing the best available evidence on pharmacotherapy can optimize patient clinical outcomes. Objective: This overview aimed to identify in systematic reviews the effects of pharmacotherapy on fibromyalgia, considering the quality of the reviews and the efficacy of the outcomes. Methods: This search was performed in seven databases: PubMed, Web of Science, COCHRANE, Lilacs, Embase, Scopus and IPA. The methodological quality was evaluated using A MeaSurement Tool to Assess Systematic Reviews 2. The protocol was registered in the PROSPERO database (CRD42018095943). Results: A total of 63 systematic reviews were selected after reading full texts, but only 8 of them were of moderate to high quality and were included in this overview. All included reviews were published in English, between 2012 and 2018, performed meta-analysis, used the American College of Rheumatology (1990) diagnostic criteria for fibromyalgia, and jointly assessed pain improvement, adverse reactions, and withdrawal. Most reviews included only randomized controlled trials. Of the fourteen drugs addressed in systematic reviews evaluated, duloxetine, milnacipran, and pregabalin showed evidence of improvement in pain (Moderate: ≤30%) and other fibromyalgia symptoms, as depression and fatigue. However, these medications presented significant withdrawals due to adverse reactions (mainly nausea, headache, dizziness and constipation). The rate of treatment withdrawal reached 36%. Conclusion: Few studies have high quality and sufficient evidence on the effect of medicines on fibromyalgia, resulting in a lack of support for prescribers to choose drugs that meet criteria for need, effectiveness, safety and compliance.

Fibromialgia é um distúrbio de processamento da dor debilitante e crônico, em que a proporção de pacientes que obtêm bons resultados com a farmacoterapia é pequena. No entanto, escolher a melhor evidência disponível sobre a farmacoterapia pode otimizar os resultados clínicos do paciente. Objetivo: Esta overview teve como objetivo identificar em revisões sistemáticas os efeitos da farmacoterapia na fibromialgia, considerando a qualidade das revisões e a eficácia dos resultados. Métodos: Esta busca foi realizada em sete bases de dados: PubMed, Web of Science, COCHRANE, Lilacs, Embase, Scopus e IPA. A qualidade metodológica foi avaliada usando A MeaSurement Tool to Assess Systematic Reviews 2. O protocolo foi registrado no PROSPERO (CRD42018095943). Resultados: Um total de 63 revisões sistemáticas foram selecionadas após a leitura de textos completos, mas apenas 8 delas eram de qualidade moderada a alta e foram incluídas nesta overview. Todas as revisões incluídas foram publicadas em inglês, entre 2012 e 2018, realizaram meta-análises, utilizaram os critérios de diagnósticos do American College of Rheumatology (1990) para fibromialgia e avaliaram conjuntamente a melhora da dor, reações adversas e retiradas. A maioria das revisões incluiu apenas ensaios clínicos randomizados. Dos quatorze medicamentos abordados nas revisões sistemáticas avaliadas, duloxetina, milnaciprano e pregabalina mostraram evidências de melhora da dor (moderada: ≤30%) e de outros sintomas da fibromialgia como depressão e fadiga. No entanto, esses medicamentos apresentaram retiradas significativas devido a reações adversas (principalmente náusea, cefaleia, tontura e constipação). A taxa de abandono ao tratamento chegou a 36%. Conclusão: Poucos estudos apresentam evidências suficientes e de alta qualidade sobre o efeito dos medicamentos na fibromialgia, resultando na falta de apoio para os prescritores escolherem medicamentos que atendam aos critérios de necessidade, eficácia, segurança e adesão.

Comportamiento clínico radiológico de la enfermedad intersticial difusa sintomática en pacientes con afecciones reumatológicas / Clinical radiological behavior of symptomatic diffuse interstitial disease in patients with rheumatological conditions

Introducción: Las enfermedades pulmonares intersticiales difusas constituyen un grupo amplio de afecciones, con manifestaciones clínicas, expresión radiológica y alteraciones funcionales del intersticio pulmonar. Objetivo: Describir el comportamiento clínico y radiológico de la enfermedad intersticial difusa sintomática en pacientes diagnosticados con enfermedades reumáticas. Métodos: Se realizó un estudio observacional, descriptivo transversal, con una población compuesta por 33 pacientes con manifestaciones respiratorias secundarias a enfermedades reumáticas entre enero de 2020 a enero de 2021 en el Hospital Universitario Clínico Quirúrgico Arnaldo Milián Castro. La muestra estuvo conformada por la totalidad de los pacientes. El análisis estadístico se llevó a cabo por medio de estadística descriptiva de cada variable. Resultados: Existió un mayor número de mujeres afectadas (75,8 por ciento) por esclerosis sistémica (31 por ciento), artritis reumatoide (27 por ciento) y lupus eritematoso sistémico (21 por ciento). La afectación respiratoria predominante fue de 81,8 por ciento con compromiso intersticial asociada a un patrón radiológico de neumonitis intersticial usual con 5 casos (21,4 por ciento), todos ligados a artritis reumatoide. Para 25 casos (75,8 por ciento) hubo un retraso diagnóstico menor de 1 año; la enfermedad reumática antecedió a la manifestación respiratoria en 21 casos (63,6 por ciento). Conclusiones: El compromiso intersticial fue la manifestación respiratoria más frecuente; los patrones de neumonitis intersticial usual y la neumonía intersticial no específica predominaron como hallazgos imagenológicos. La secuencia diagnóstica apuntó hacia las enfermedades reumáticas como el debut del proceso(AU)

Introduction: Diffuse interstitial lung diseases constitute a wide group of conditions, with clinical manifestations, radiological expression and functional alterations of the pulmonary interstitium. Objective: To describe the clinical and radiological behavior of symptomatic diffuse interstitial disease in patients diagnosed with collagenosis. Methods: An observational, descriptive, cross-sectional study was carried out. The population consisted of 33 patients with respiratory manifestations secondary to rheumatic diseases. The sample consisted of all the patients. Statistical analysis was carried out by means of descriptive statistics for each variable. Results: There was a greater number of women affected (75.8 percent) by systemic sclerosis (31percent), rheumatoid arthritis (27 percent) and systemic lupus erythematosus (21 percent). The predominant respiratory involvement was 81.8 percent with interstitial involvement associated with a radiological pattern of usual interstitial pneumonitis with 5 cases (21.4 percent), all linked to rheumatoid arthritis. For 25 cases (75.8 percent) there was a diagnostic delay of less than 1-year, rheumatic diseases preceded the respiratory manifestation in 21 cases (63.6 percent). Conclusions: Interstitial involvement was the most frequent respiratory manifestation; the patterns of usual interstitial pneumonitis and nonspecific interstitial pneumonia as predominated imaging findings. The diagnostic sequence pointed towards rheumatic diseases were the debut of the process(AU)

Reumatólogos frente al papeleo: evaluación de la carga administrativa en un Servicio de Reumatología / Rheumatologists versus paperwork: assessment of administrative burden in a Rheumatology Service

Introducción: los resúmenes de historia clínica (RHC), confeccionados por reumatólogos, los solicitan los pacientes para realizar diversos trámites. Su incumplimiento afecta el acceso a las prestaciones sanitarias e implica que los médicos destinen tiempo a un requisito puramente burocrático. Los objetivos de este estudio fueron: determinar la frecuencia de RHC solicitados y realizados en nuestro Servicio durante un semestre y el tiempo dedicado a dicha tarea; describir los motivos de las solicitudes y las características de los solicitantes. Materiales y métodos: se incluyeron todos los pacientes que solicitaron ≥1 RHC en el último semestre de 2019. Se registraron características sociodemográficas, enfermedad de base y motivos de solicitud. Se consideró, como parámetro de comparación, una duración predeterminada de 15 minutos por consulta médica. Resultados: se registraron 103 solicitantes de RHC en 3159 citas programadas en 152 días. Se realizaron 144 RHC (0,95/día). Un 18% solicitó uno nuevo en el mismo intervalo. El tiempo promedio para la confección de cada resumen fue de 75 minutos. El tiempo total dedicado a estas tareas administrativas en el semestre evaluado fue el equivalente a 720 citas potenciales, aproximadamente un 20% de los turnos programados ofrecidos. La mayoría se emitió para solicitar medicamentos crónicos, principalmente para artritis reumatoidea, y con cobertura médica pública. Conclusiones: el tiempo destinado a confeccionar RHC por motivos administrativos fue el equivalente a un aumento potencial de más del 20% de las citas médicas.

Introduction: medical history summaries (MHS) issued by rheumatologists are requested by patients for various procedures. Not completing them denies access to health benefits, this implies that physicians spend time on a purely bureaucratic requirement. The objectives were: to determine the frequency of MHS requested and issued in our service during a semester and the time dedicated to them; to describe the reasons for the request and the characteristics of the applicants. Materials and methods: all patients who request ≥1 MHS in the last semester of 2019 were included. Sociodemographic characteristics, underlying disease and reasons for request were recorded. As a comparison measure, a predetermined duration of 15 minutes per medical appointment was expected. Results: 103 MHS applicants in 3159 scheduled appointments in 152 days. 144 MHS were performed (0.95/day). 18% requested a new one in the same interval. The average time in the preparation of a MHS was 75 minutes. The total time spent on these during the evaluated semester was equivalent to 720 potential appointments, approximately 20% of scheduled appointments that were granted. Most were issued to request chronic medications, mainly in rheumatoid arthritis and public health care. Conclusions: the time spent to prepare MHS for administrative reasons was comparable to a potential increase of more than 20% in medical appointments.

Nuevo panorama para las enfermedades reumáticas pediátricas / New landscape for pediatric rheumatic diseases

Introducción: Las enfermedades reumáticas no se limitan a la edad adulta. Afectan a personas de todas las edades, incluidos los niños, y a menudo afectan a adultos jóvenes. En consecuencia, las enfermedades reumáticas pediátricas necesitan una evaluación y un seguimiento minuciosos y cuidadoso. Pueden ser debilitantes y, si no se tratan adecuadamente, pueden poner en peligro la vida. Objetivos: En este artículo se comentará sobre avances en el diagnóstico y tratamiento de las enfermedades reumáticas pediátricas, destacando las ventajas del empleo de determinados medios diagnósticos. Desarrollo: Para ello se ha realizado una revisión bibliográfica que permite aportar elementos importantes a considerar. Conclusiones: Se ha avanzado mucho en las últimas décadas en el campo de la reumatología pediátrica, que incluyen, entre otros, la patogenia, los criterios de clasificación y las terapias. Los reumatólogos pediátricos deben mantenerse al día con el progreso para aumentar la precisión del diagnóstico y mejorar el pronóstico de los pacientes(AU)

ABSTRACT Introduction: The effective treatment of postoperative pain is today a challenge for anesthetists, rheumatologists, orthopedic surgeons, surgeons and researchers of various specialties, who constantly propose protocols based on scientific evidence. Objective: Reflect and open the debate regarding the role of anesthesia in the relief of pain of rheumatological origin. Development: In Rheumatology, it is recommended, in all patients with chronic rheumatic pain, to calculate the intensity of the pain, both for the first choice of the analgesic treatment and for the measurement of the response. And, for this, several methods of quantification have been proposed. Conclusions: Diagnostic management and multidisciplinary treatment preside when this type of case is examined, since it is the only way to identify the origin of pain and provide prudent relief. In general, patients respond to conservative treatment and only a small group will need invasive anesthetic techniques(AU)

Manifestaciones oftalmológicas en pacientes con enfermedades reumáticas en edades pediátricas / Ophthalmologic manifestations in patients with rheumatic diseases in pediatric ages

El diagnóstico de las enfermedades reumatológicas en los niños supone un gran impacto para el paciente, padres y familiares. Uno de cada 1.000 niños podría sufrir una enfermedad reumatológica. Los síntomas del sistema locomotor son un motivo de consulta frecuente. Las enfermedades reumáticas producen un gran número de manifestaciones sistémicas, muchas de ellas incapacitantes, entre las que se encuentran las alteraciones oftalmológicas que aparecen en un porciento elevado de casos. Para poder diagnosticarlas es fundamental en primer lugar conocerlas, su diagnóstico precoz permite el tratamiento adecuado para evitar complicaciones como la disminución o pérdida visual irreversible en muchos casos. En este trabajo se realizó una búsqueda automatizada con el objetivo de encontrar información actualizada sobre el tema y describir las lesiones oculares observadas en pacientes pediátricos con afecciones reumáticas e identificación temprana de signos predictivos del desarrollo de las mismas(AU)

The diagnosis of rheumatologic diseases in children denotes a great impact for the patient, parents and relatives. One in every 1,000 children could suffer from a rheumatologic disease. Symptoms of the locomotor system are a frequent reason for consultation. Rheumatic diseases produce a large number of systemic manifestations, many of them disabling, including ophthalmologic alterations which appear in a high percentage of cases. In order to be able to diagnose them, it is essential to know them first of all, their early diagnosis allows the appropriate treatment, to avoid complications such as irreversible visual decrease or loss in many cases. In this work an exhaustive automated search was carried out in order to find updated information on the subject and to describe the ocular lesions observed in pediatric patients with rheumatic diseases and early identification of predictive signs of their development(AU)